The use of anabolic androgenic steroids (AASs) among non-athletes is a public health-problem, as abusers underestimate the negative effects associated with these drugs. The present study investigated the toxic effects of testosterone, nandrolone, stanozolol, and trenbolone, and aimed to understand how AAS abuse affects the brain. Mixed cortical cultures from embryonic rats were grown in vitro for 7 days and thereafter treated with increasing concentrations of AASs for 24 hours (single-dose) or 3 days (repeated exposure). Cells were co-treated with the androgenreceptor (AR) antagonist flutamide, to determine whether the potential adverse effects observed were mediated by the AR. Cellular toxicity was determined by measuring mitochondrial activity, lactate dehydrogenase (LDH) release, and caspase-3/7 activity. Nandrolone, unlike the other AASs studied, indicated an effect on mitochondrial activity after 24 hours. Furthermore, singledose exposure with testosterone, nandrolone and trenbolone increased LDH release, while no effect was detected with stanozolol. However, all of the four steroids negatively affected mitochondrial function and resulted in LDH release after repeated exposure. Testosterone, nandrolone, and trenbolone caused their toxic effects by induction of apoptosis, unlike stanozolol that seemed to induce necrosis. Flutamide almost completely prevented AAS-induced toxicity by maintaining mitochondrial function, cellular integrity, and inhibition of apoptosis.
Introduction
Testosterone and other synthetic anabolic androgenic steroids (AASs) are commonly abused in order to enhance athletic performance and physical appearance (Kindlundh et al., 1998 (Kindlundh et al., , 1999 Cohen et al., 2007) . The average age-of-onset for AAS use is around 20 years and only 22% of the users start before age 20 (Pope et al., 2014) . The worldwide prevalence of AAS abuse is poorly understood, but a high frequency of usage occurs in certain subpopulations, for example in gym communities. In these environments the prevalence of usage among male young adults have been reported to be as high as 9.8 % (Althobiti et al., 2018) . Many of the misused compounds have not been adequately examined regarding their effect on general health, and even less is known about their effects on the brain. Because of this it is of importance to gain more knowledge about the acute and long-term adverse effects induced by these substances.
It is well known that AASs induce androgenic effects (development of male sex characteristics) or anabolic effects (muscle building), by actions mediated through the intracellular androgen receptor (AR), which regulates transcription in targeted genes (Lee and Chang, 2003) . Structural optimization of the testosterone molecule has subsequently been conducted with the aim of developing AASs with enhanced anabolic effects relative to the androgenic effects. However, all AASs so far available on the market still cause masculinization when used in high doses and over a long period of time (Kicman, 2008) . Regimens of AAS misuse often involve doses ranging up to 100 times higher than the therapeutic dose of testosterone that is applied. Doses are often increased gradually during 6-12 weeks, thereafter decreased and followed by a variable period off the drugs (Kanayama et al., 2009 ).
In addition to the desired effects, high doses and extended treatment periods with AASs also cause adverse effects, which have been extensively reviewed elsewhere (Goldman and Basaria, 2018) . Furthermore, there are a number of known psychological effects seen in AAS users, such as irritability, anxiety, and aggression (Kanayama et al., 2008; Lindqvist Bagge et al., 2017) , which suggest that these steroids affect the brain. Although the impact of AASs on the central nervous system (CNS) is not yet fully clarified, several studies report that these compounds may interact with a variety of neurochemical systems in the rodent brain (Le Greves et al., 1997; Hallberg et al., 2000; Kindlundh et al., 2002; Clark and Henderson, 2003; Hallberg, 2011; Gronbladh et al., 2014) . Supraphysiological doses of AAS may produce a variety of neurotoxic effects, which are mechanistically more or less explored. Previous in vitro studies suggest a negative impact on cell survival induced by AASs in neuronal-like cells (Estrada et al., 2006; Orlando et al., 2007; Caraci et al., 2011; Basile et al., 2013) . These studies suggest neurodegenerative alterations to be caused either by direct induction of apoptosis (Estrada et al., 2006; Basile et al., 2013) or indirectly by increasing neuronal vulnerability to other toxic insults (Orlando et al., 2007; Caraci et al., 2011) .
This opens up for speculations regarding the risk of cognitive deficits among AAS-abusers.
Furthermore, a number of studies indicate that AASs may affect several CNS-related behaviors
and the studies which demonstrate that different AASs may induce memory impairment in both rats and humans (Magnusson et al., 2009; Tanehkar et al., 2013; Kanayama et al., 2013; Gronbladh et al., 2013; Heffernan et al., 2015) have received particular interest. The underlying mechanism behind these observations still remains to be clarified, but prolonged exposure to AASs is shown to cause smaller cortical volume and thinning of the cortex among AAS-users , which suggests that AASs may induce cerebral atrophy. Furthermore, structural and functional connectivity alterations of amygdala have also been reported in men after long-term AAS use (Kaufman et al., 2015; Westlye et al., 2017; Seitz et al., 2017) . The alterations seen in amygdala may affect networks between brain areas associated with cognitive and emotional control. Taken together, this strengthens the theory about the potentially increased risk of persistent alterations in the brain, behavioral changes, and development of neurodegenerative diseases among AAS-users.
Testosterone, nandrolone, stanozolol, and trenbolone are all commonly abused by AAS-users in their efforts to gain muscle and improve performance. The chemical structures of these AASs are depicted in Figure 1 . In the present study, supra-physiological concentrations of structurally different AASs caused cellular toxicity in primary cortical cell cultures, but to different extents.
These differences between the AASs regarding their effects on mitochondrial function, cell membrane integrity, and activation of specific executioner caspases are of relevance in order to understand the mechanisms underlying the AAS-induced effects on the brain that result in behavioral and cognitive changes.
Experimental Procedures

Animals and Tissue collection
All animal experimental procedures were approved by the local animal ethics committee at Uppsala University (C15/14) and were conducted in accordance with Swedish guidelines regarding animal experiments (Animal Welfare Act SFS 1998:56) and the European Communities Council directive (86/609/EEC).
Pregnant rats, Sprague-Dawley or Wistar, were obtained from Charles River (Sulzfeld, Germany).
Mixed glial and neuronal primary cortical cultures were prepared according to a previously described method with minor modifications (Diwakarla et al., 2016) . Briefly, pregnant dams, (n = 10), were anesthetized at embryonic day 17 with increasing concentrations of carbon dioxide.
Fetuses were extracted from the mothers and cortical tissue was dissected in Hank´s balanced salt solution (Thermo Fisher Scientific, Waltham, MA, USA).
Cell culture
Tissue was prepared by digestion with 0.4 mg/mL trypsin (Sigma-Aldrich, St Louis, MO, USA) at 37°C for 10 minutes. The chemical digestion was inhibited with 0.5 mg trypsin inhibitor (SigmaAldrich), and a cell suspension was obtained by mechanical dissociation with a 1 mL pipette.
Cells were counted and seeded at appropriate densities into pre-coated Poly-D-lysine (50 µg/mL, Sigma-Aldrich) tissue culture plates (Thermo Fischer Scientific). Cells were grown for 24 hours in neurobasal media (Thermo Fisher Scientific) supplemented with 2 % (v/v) B27 (Thermo Fischer Scientific), 10 % (v/v) fetal bovine serum (Thermo Fischer Scientific), 0.5 mM GlutaMAX™ (Thermo Fischer Scientific), and 100 U/mL penicillin and streptomycin (Thermo Fisher Scientific). At day one in vitro (1 DIV), media was replaced with serum-free media supplemented with 2 % extra B27 (Thermo Fischer Scientific). Cell cultures were kept in an incubator (37°C/5% (v/v) CO 2 ) and subsequent partial media replacements were performed twice a week.
Only mature cell cultures (7 days in vitro, 7 DIV) were used for the experiments.
Chemicals and Drug treatments
The AASs (testosterone, nandrolone, stanozolol, trenbolone) antibody Alexa 488 donkey anti-rabbit (1:500 dilution; Thermo Fischer Scientific) was added for 1 hour at room temperature. After washing, cover slips were mounted with MOWIOL anti-fade mounting medium (Sigma-Aldrich) containing 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI; 2.5:500 dilution; Merck Millipore, Bedford, MA, USA). Images were acquired using ×20 objectives on the ImageXpress XL (Molecular Devices, San Jose, CA, USA) microscope.
Cell viability assay
To investigate the effect of AASs on the viability of primary cortical cell cultures, a density of 1×10 5 cells per well were seeded into a 96-well tissue culture plate (Thermo Fisher Scientific), and the cells were exposed to either increasing concentrations of AASs alone or together with flutamide at 7 DIV for 24 hours, (n =4 ), and 3 days, (n = 4). Following drug treatments, mitochondrial function as a measure of cell viability was determined using the MTT assay (Sigma-Aldrich). The absorbance was measured using the FLUOstar Omega spectrophotometer (BMG Labtech, Ortenberg, Germany) at 570 nm.
Cell cytotoxicity assay
To study whether exposure to the AASs cause membrane permeabilization in primary cortical cell cultures, a density of 1×10 5 cells per well were seeded into a 96-well tissue culture plate (Thermo Fisher Scientific). At 7 DIV the cells were exposed to increasing concentrations of AASs, with or without flutamide, for 24 hours, (n = 4), and 3 days, (n = 4). After the drug treatments, cell cytotoxicity was studied by measuring the release of lactate dehydrogenase (LDH). LDH is an enzyme naturally occurring in the cell cytoplasm, which upon cell membrane permeabilization leaks out into the cell media and acts as a marker for cell cytotoxicity. Culture media from cells exposed to AASs for 24 hours or 3 days was transferred to an empty tissue culture plate. LDH concentration was analyzed using the LDH cytotoxicity detection kit (Roche Life Science, Mannheim, Germany) according to the manufacturer's instructions. The absorbance was measured at 492 nm using the FLUOstar Omega spectrophotometer (BMG Labtech). Wells containing media-only (background noise) were subtracted from each well.
Caspase-3/7 activity
Apoptosis is a process of programmed cell death, which occur in all cells. The onset of apoptosis is regulated by specific caspases that mediate proteolytic cleavage of certain proteins. Therefore, detection of active caspases can be used as a marker of apoptosis. To analyze whether exposure to AASs induced apoptosis in primary cortical cell cultures, a density of 2×10 4 cells per well were seeded into a 96-well tissue culture plate (Thermo Fisher Scientific). At 7 DIV the cells were either exposed to increasing concentrations of AASs alone or together with flutamide, for 24 hours and 3 days, (n = 3). Staurosporine (100 nM; Sigma-Aldrich), a well-known apoptotic inducer was used as a positive control to ensure detection of caspase activity (data not shown).
After the drug treatments, apoptosis was studied by analyzing the activity of caspase 3 and caspase 7 using the Caspase 3/7 GLO kit (Promega, Madison, WI, USA) according to the manufacturers instruction with some modifications. Briefly, the caspase 3/7-GLO reagent buffer was added (v/v) to the tissue culture plate, containing treated and untreated cells. From this time point on the contents was protected from light. The tissue culture plate was placed on a shaker at 300 rpm for 5 min and thereafter incubated for 30 min at room temperature. The contents were then transferred to an empty white-walled 96-well plate (Thermo Fisher Scientific) and luminescence was analyzed using the FLUOstar Omega spectrophotometer (BMG Labtech).
Statistical analysis
For all measurements, raw data was used for the statistical analyses. Raw data was assumed to follow normal distribution and the statistical choises were based on previous report (Lew, 2007) .
Cells collected from fetuses obtained from one individual rat were considered as one individual culture (n = 1). Each individual culture received specific treatment in triplicates and all analyses were repeated at least three times in individual cultures (n = 3). The statistical test used was the two-way analysis of variance (2-way ANOVA), with specific treatment and experiment (culture ID) as factors to account for differences. When an overall effect was found on treatment, data were further analysed by Dunnet´s post hoc test, and corrected for multiple comparison using statistical hypothesis testing. The MTT and LDH-analyses of treatments with AASs alone and together with flutamide were performed on individual cultures and considered independent experiments. Therefore, data received from these experiments were handled and analysed individually. In contrast to this, experimental analysis of caspase 3/7 activity in cells treated with AAS alone and together with flutamide were performed on the same individual cultures. Data from these experiments were therefore handled, analysed, and presented together. Data are presented as mean values and standard error of mean (mean  SEM). For all statistical analyses a probability value of p<0.05 was considered statistically significant. Graphpad software (Prism 7.0) was used to assess the statistical analyses.
Results
To investigate the potential toxic effects of supra-physiological doses of certain structurally diverse AASs, an in vitro model of mixed glial and neuronal cortical cell cultures was used. Mature cortical cultures (7 DIV) showed prominent axonal maintenance and contained approximately 60 % neurons as measured by microtubule-associated protein 2-positive cells.
Primary cortical cultures expressed the androgen receptor
The immunocytochemistry analysis revealed expression of the AR in primary cortical cell cultures ( Figure 2 ) and the cells could therefore be used for further analyses in the present study. The AR was primarily found to be expressed in the cell body associated with the nuclei, but also in extranuclear sites such as axons.
Single-dose exposure to nandrolone had an effect on mitochondrial function in primary cortical cultures
Treatment with nandrolone (single-dose exposure for 24 hours) had an overall effect on mitochondrial activity, F (3, 9) = 4.323, p0.05, however, post hoc analysis did not reveal any significant differences (Figure 3 ). Single-dose exposure to testosterone, stanozolol, and trenbolone did not alter the overall effect on mitochondrial function (Figure 3 ).
Single-dose exposure to testosterone, nandrolone, and trenbolone caused membrane permeabilization in primary cortical cultures
An overall effect could be detected on LDH release following 24 hours treatment with testosterone, F (3, 9) = 10.14, p0.01, nandrolone, F (3, 9) = 7.246, p0.01, and trenbolone, F (3, 9) = 4.325, p0.05, indicating membrane permeabilization. Stanozolol did not affect the release of LDH. The post hoc analysis revealed that exposure to high concentrations (100 M) of testosterone, nandrolone, and trenbolone significantly increased LDH release when compared with control ( Figure 4 ).
Repeated exposure to the AASs caused reduced mitochondrial function and increased membrane permeabilization in primary cortical cultures
Repeated administration (every 24 hours for 3 days) with testosterone, F (3, 9) = 17.04, p0.001, nandrolone, F (3, 9) = 29.9, p0.0001, stanozolol, F (3, 9) = 5.781, p0.05, and trenbolone, F (3, 9) = 10.76, p0.01, resulted in an overall reduction in mitochondrial function, indicating reduced viability of the cells. The following post hoc analysis showed that nandrolone reduced mitochondrial function at both 30 M and 100 M, while the other AASs only caused mitochondrial dysfunction at the highest dose (100 M) when compared with control ( Figure 5 ).
An overall effect on LDH release after repeated administration with testosterone, F (3, 9) = 28.22, p0.0001, nandrolone, F (3, 9) = 46.79, p0.0001, stanozolol, F (3, 9) = 23.84, p0.0001, and trenbolone, F (3, 9) = 8.2, p0.01, could also be detected. The post hoc analysis revealed that nandrolone and trenbolone increased LDH release at both 30 M and 100 M, while a significant increase in LDH could only be detected at 100 M following testosterone and stanozolol treatment when compared with control ( Figure 6 ).
The toxic effects induced by the AASs are mediated by androgen receptor activation
The AR antagonist flutamide prevented the overall reduction in mitochondrial activity seen after single-dose exposure to nandrolone (data are presented in table 1), as no reduction in viability was observed following co-treatment. In addition, flutamide was able to rescue cells from the mitochondrial dysfunction induced by repeated exposure of testosterone and stanozolol, as no reduction in viability was detected following co-treatment (data are presented in table 1).
Furthermore, flutamide was able to reduce the overall negative effect seen on mitochondrial function caused by repeated exposure of nandrolone F (3, 9) = 14.97, p0.001, and trenbolone, F Flutamide inhibited the increased membrane permeabilization detected after single-dose exposure to testosterone, nandrolone, and trenbolone, as no significant cytotoxic effect (LDH release) was detected after co-treatment (data presented in table 2). In addition, co-administration with flutamide reduced the amount of LDH released after repeated exposure of testosterone and stanozolol to similar levels as control. The overall cytotoxic effect induced by nandrolone, F (3, 9) = 7.713, p0.01, and trenbolone, F (3, 9) = 6.646, p0.05, was reduced by flutamide, but not to control levels. Post hoc analyses demonstrated that the effect seen with 30 M of nandrolone was prevented by flutamide, but the effect seen at 100 M was only partly inhibited. In addition, the post hoc test revealed no cytotoxic effect at any concentration during co-treatment with flutamide and trenbolone (data presented in table 2).
Testosterone, nandrolone, and trenbolone, unlike stanozolol, induced apoptosis in primary cortical cultures through activation of the androgen receptor Testosterone, nandrolone, and trenbolone caused apoptotic cell death. Activation of caspase 3 and caspase 7 were detected after single-dose exposure to nandrolone, F (6, 12) = 4.894, p0.01, and trenbolone, F (6, 12) = 3.293, p0.05. Caspase 3/7 activity was prevented by coadministration with flutamide ( figure 7b and 7d) . Furthermore, the activation of caspase 3 and 7
were detected after repeated exposure to testosterone, F (6, 12) = 15.58, p0.0001, and the effect could be reduced by flutamide (figure 7e). Repeated administration with nandrolone, F (6, 12) = 8.092, p0.001, and trenbolone, F (6, 12) = 7.9, p0.001, further increased caspase 3/7 activity and the activation was prevented by flutamide ( figure 7f and 7h) . The post hoc analyses revealed that single-dose and repeated administration with high doses (100 M) of AASs induced caspase-3/7 activity when compared with controls. In contrast, neither single-dose nor repeated administration with stanozolol induced apoptosis in primary cortical cell cultures (figure 7c and 7g) as activation of caspase 3 and caspase 7 could not be detected. Flutamide did not affect caspase activity of primary cortical cultures when administered alone (data not shown).
Discussion
The present study demonstrates certain structurally diverse AASs to cause reduction in cell viability and increase in cell cytotoxicity. This was evidenced by reduced mitochondrial activity and elevated levels of LDH, respectively, occurring in a dose-dependent and time-dependent manner. In addition, the toxic properties of testosterone, nandrolone, stanozolol, and trenbolone in these assays diverged.
The cell viability and cell cytotoxicity were altered at the highest concentrations of AASs (30-100 M) used in the present study. These findings support previous reports suggesting that AAS affect cell survival at micro-molar concentrations causing decreased cell viability in cultured cells (Estrada et al., 2006; Cunningham et al., 2009; Caraci et al., 2011; Basile et al., 2013; Ma and Liu, 2015) . In accordance with the results presented herein, no detection of any AAS-induced toxicity at 10 uM was reported in a previous study (Orlando et al., 2007) . Interestingly, this concentration, and even nano-molar concentrations, were found to enhance excitotoxic cell death. This raises serious concerns as excitotoxic mechanisms can be triggered by several insults, as well as of an underlying neurodegenerative disease (Orlando et al., 2007) . Notably, micro-molar concentrations of AASs are previously established in the cerebrospinal fluid of chronic AAS-abusers (Daly et al., 2001 ). The cortical cell death detected herein could be one explanation for the smaller cortical volume and thinner cortex seen among AAS-using weightlifters , where the extent of the effects are associated with longer history of AAS exposure and, based on present results, possibly by the type of AAS used. With respect to the parameters assessed, nandrolone appeared to be the most toxic AAS, while testosterone, stanozolol, and trenbolone disposed similar effects but to a lesser extent. According to the present results, the order of the examined AASs regarding their toxicity was found to be nandrolone > trenbolone > testosterone > stanozolol.
Alterations in the brain following misuse of AASs correlates with behavioral changes including decreased cognitive function (Kanayama et al., 2013) . In several independent rodent studies nandrolone decanoate is described to impair social memory (Kouvelas et al., 2008) , and spatial memory and learning (Magnusson et al., 2009; Tanehkar et al., 2013) . Also, there is a report indicating deficits in visuospatial memory of AAS-users, where the severity of the deficits is associated with total life-time exposure to AASs (Kanayama et al., 2013). AAS-users are also shown to display alterations in brain areas and neurochemical systems involved in cognitive control (Kaufman et al., 2015) . However, indications from an early study in rodents show that other AASs, like testosterone cypionate, may not affect spatial memory and learning (Clark et al., 1995) , supporting the hypothesis that structurally diverse AASs exert different effects.
It is known that AASs induce apoptosis in different tissues and organs (Wiren et al., 2006; Shokri et al., 2010; Janjic et al., 2012; Pomara et al., 2015) , and therefore represents an essential mechanism in AAS-induced toxicity. There are primarily two major signaling pathways that activate apoptotic cell death; the mitochondrial pathway (intrinsic pathway) and the death receptor pathway (extrinsic pathway). Both signaling pathways result in activation of caspase proteases, where caspase 3 and caspase 7 are the executioner caspases (Green and Llambi, 2015) .
Dysregulation of apoptosis is associated with neurodegenerative disorders (Agostini et al., 2011) , hence, long-term in vivo exposure to certain AASs might increase the susceptibility to the onset or progression of neurodegenerative diseases later in life. The present study demonstrated testosterone, nandrolone, and trenbolone to induce apoptosis in cortical cultures in a dosedependent and time-dependent manner, as indicated by activation of the executioner caspases. In contrast, stanozolol did not induce apoptosis, neither after single nor repeated administration.
Therefore, it is most likely that stanozolol caused its toxic effects by initiation of necrosis, i.e. a form of cell damage leading to premature death of cells in living tissue by autolysis. The AASinduced caspase 3/7 activation and the decrease in mitochondrial function detected in the present study, indicate that the intrinsic pathway is responsible for the induced apoptosis. These results are supported by similar findings from some investigators (Basile et al., 2013) , whereas others have suggested testosterone to cause cell death via the extrinsic apoptotic pathway (Lopes et al., 2014) . Overlap between the two signaling pathways has been reported. Therefore, specific stimuli may cause a particular type of of cell death dependent on the cell type investigated and neighboring cells present (Green and Llambi, 2015) .
In order to establish whether the AAS-induced toxic effects were mediated by the AR or not, the cells were co-treated with the AR-antagonist flutamide. Flutamide prevented the alterations detected in all asseys used in the present study (MTT metabolism, LDH relese and caspase 3/7 activity) after single-dose treatment with the AASs. This strongly supports the single-dose effects to be mediated by the AR. Moreover, dependent on type of AAS studied flutamide was able to either inhibit or decrease the effects detected after repeated treatment. Flutamide abolished the caspase 3/7 activation after repeated treatment, suggesting the induction of the apoptotic cascade to be dependent on AR-activation. Effects caused by testosterone or stanozolol on MTT metabolism and LDH release were inhibited by flutamide, while effects induced by nandrolone and trenbolone were decreased, but not to control levels. A possible explanation could be that the concentration of flutamide used was too low to compete with the highest concentration of nandrolone and trenbolone. However, as the caspase activation caused by these AASs was inhibited by flutamide at this high concentration, the results could instead indicate that some toxic effects induced by nandrolone and trenbolone, at least in part, were mediated through another pathway apart from AR-activation.
The pharmacological differences between the AASs studied might explain the diverged toxicity detected to some extent. Nandrolone has a high ratio regarding anabolic versus androgenic properties and because of this it is one of the most frequently abused steroids. In contrast to testosterone, nandrolone has higher binding affinity to the AR. However, while testosterone is reduced in vivo by 5-reductase to the high-affinity ligand dihydrotestosterone (DHT), nandrolone is reduced to deliver a metabolite, 5-dihydro-19-nortestosterone, with poorer AR affinity. In addition, nandrolone is a poor substrate to aromatase in comparison to testosterone, and is not aromatized to estradiol to the same extent (Ryan, 1959) . Furthermore, stanozolol has much weaker binding affinity to the AR compared to both testosterone and nandrolone (Saartok et al., 1984) , which may be a possible explanation for the lower toxicity demonstrated by stanozolol in the present cell assays. However, even though stanozolol exhibits a low binding affinity, it is described as a potent activator of the AR (Feldkoren and Andersson, 2005) .
Trenbolone is a nandrolone-derivative and is neither aromatized nor converted by 5-reductase, which makes it more androgenic compared to nandrolone (Yarrow et al., 2010) . Also, trenbolone has the highest relative binding affinity to the AR of the four AASs studied (Scippo et al., 2002) .
Nevertheless, trenbolone is shown to have a lower potency to the AR compared to nandrolone (Death et al., 2004) .
Based on the literature (Saartok et al., 1984; Scippo et al., 2002) , the order of relative binding affinity of the AASs in the present study is trenbolone > nandrolone > testosterone > stanozolol. This ranking is similar, but not quite comparable, to the AASs toxicity shown in this study, which suggests that the degree of physical binding to the receptor does not fully explain the biological activity of the AAS. This suggests that nandrolone may induce its effects by an alternative mechanism other than that through the classical AR pathway. Specific ligand-induced effects are proposed to depend on how the AAS-AR complex interacts with co-regulators and other transcription factors (Holterhus et al., 2002) resulting in enhanced or suppressed transcription of specific genes. In addition, AASs are suggested to cause non-genomic effects either by activation of membrane-bound AR (Foradori et al., 2008) or by modulation of receptors in other signaling systems (Bitran et al., 1993; Yang et al., 2005) .
In the present study stanozolol was the AAS that deviated the most from the other steroids investigated. Stanozolol only affected the cells after repeated administration with the highest concentration (100 M) used and was the only AAS that seemed to induce necrosis. Differences between stanozolol and other types of AASs are previously noted in the literature with regards to psychological behavior (Breuer et al., 2001 ). The present results suggest that stanozolol probably exerts its effects on the brain by a different molecular mechanism compared to the other AASs studied, which may explain various behavioral profiles recorded for these steroids.
We believe the present study provides important information regarding the toxic effects of different AASs, doses and administration regimens. Furthermore, we would like to highlight some potential limitations of the study. The model used (rat embryonical cortical cell cultures) was selected based on its advantages to cell lines. Primary cell cultures retain many of the physiological and biochemical features, making them useful to study pathways or isolated mechanisms of interest. However, the embryonic cultures do not reflect the intact CNS and therefore it is desirable that complementary in vivo studies are conducted in the future to elucidate this issue. The AAS concentrations used in the present study (10, 30 100 M) were chosen based on previous literature, which have shown that micro-molar but not nano-molar concentrations cause toxic effects in cultured cells (Estrada et al., 2006; Basile et al., 2013) . These concentrations should mimic the supraphysiological doses used by AAS-users, but can not be interpreted as the actual concentration the brain is exposed to. The exposure times used in the study (24 hours and 3-days) were chosen to investigate an acute effect in comparison with repeated treatment. The data from this relatively short exposure can not be directly transferred to years of AAS abuse, however, our results give insight on mechanistic differences between treatment regimens under controlled circumstances.
In conclusion, it is evident from the present study that the structurally diverse AASs induced toxic effects in primary cortical cell cultures, but to different extents. These toxic effects were primarily mediated through the AR pathway, although, nandrolone and trenbolone might induce effects independent from the AR at high concentrations. These observed alterations may contribute to the decline in learning and memory later in life that former AAS abusers have reported. The mechanism by which AASs exert their toxic effects resulting in cognitive deficiency is still a question that needs to be further addressed. Hence, the correlation between toxic effects monitored in primary cortical cultures from rat described herein, the underlying molecular mechanisms, and the cognitive impairments in rodents and humans that appear at supraphysiological concentrations of AASs is not clear. 
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